Another Injectable Toxoid Vaccine Flops for C. Diff
It's time to look at oral vaccines to prevent C. difficile infections, experts say
C Diff Drug Development
CLOVER: A Phase 3 Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection - PubMed
Three PF-06425090 doses were safe and well-tolerated. Although the primary endpoint was not met, PF-06425090 reduced symptom duration, CDI requiring medical attention, and CDI-directed antibiotic treatment, highlighting its potential to reduce CDI-associated healthcare burden. NCT03090191.
Pfizer-06425090 C Diff Vaccine Falls Short on Primary Endpoint
The Phase 3 CLOVER trial still showed safety and potential benefits by reducing C difficile infection duration, medical attention needs, and antibiotic use.
Nestlé Health Science Aquires Global Rights to Vowst
Nestlé aims to increase the global availability of Vowst, an FDA-approved therapy for preventing recurrent C difficile infection, while also seeking new opportunities for the product worldwide.
C difficile vaccine candidate fails to meet primary end point in phase 3 trial
The vaccine didn't reduce C difficile infections in at-risk adults, but it did show the potential to reduce infection severity and limit need for medical attention.
CLOVER: A Phase 3 Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection - PubMed
Three PF-06425090 doses were safe and well-tolerated. Although the primary endpoint was not met, PF-06425090 reduced symptom duration, CDI requiring medical attention, and CDI-directed antibiotic treatment, highlighting its potential to reduce CDI-associated healthcare burden. NCT03090191.
PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent Clostridioides difficile infection - PubMed
The study is registered at ClinicalTrials.gov (NCT03931941).
The end of toxoid vaccine development for preventing Clostridioides difficile infections? - PubMed
The end of toxoid vaccine development for preventing Clostridioides difficile infections?
Chemical optimization and derivatization of micrococcin p2 to target multiple bacterial infections: new antibiotics from thiopeptides - PubMed
Antimicrobial resistance poses a significant threat to humanity, and the development of new antibiotics is urgently needed. Our research has focused on thiopeptide antibiotics such as micrococcin P2 (MP2) and derivatives thereof as new anti-infective agents. Thiopeptides are sulfur-rich, structurall …
Atomic structures of a bacteriocin targeting Gram-positive bacteria - PubMed
Due to envelope differences between Gram-positive and Gram-negative bacteria, engineering precision bactericidal contractile nanomachines requires atomic-level understanding of their structures; however, only those killing Gram-negative bacteria are currently known. Here, we report the atomic struct …
Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies | Infection and Immunity
ABSTRACT Clostridium difficile is the primary cause of nosocomial antibiotic-associated diarrhea in the Western
world. The major virulence factors of C. difficile are two exotoxins, toxin A (TcdA) and toxin B (TcdB), which cause extensive colonic
...
Pantothenate kinase: A promising therapeutic target against pathogenic Clostridium species - PubMed
Current treatment of clostridial infections includes broad-spectrum antibiotics and antitoxins, yet antitoxins are ineffective against all Clostridiumspecies. Moreover, rising antimicrobial resistance (AMR) threatens treatment effectiveness and public health. This study therefore aimed to dis …
Development of two recombinant vaccines against Clostridioides difficile infection and immunogenicity in pregnant sows and neonatal piglets - PubMed
The synthesized recombinant proteins were capable of inducing antibody titers against C. difficile toxins A and B in sows, and were passively transferred to piglets through colostrum.
NASDAQAnnounces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today...
Q&A: Biologic drugs are reinvented to treat infectious diseases
Lumen scientists were the first to crack that long-standing barrier. Once that was done, we started looking around for useful applications. To our surprise, we discovered that there is actually a very robust literature on orally delivered therapeutic proteins, although most people are unaware of it.
A Novel Truncated CHAP Modular Endolysin, CHAPSAP26-161, That Lyses Staphylococcus aureus, Acinetobacter baumannii, and Clostridioides difficile, and Exhibits Therapeutic Effects in a Mouse Model of A. baumannii Infection - PubMed
Development of novel antibacterial agents is imperative due to the increasing threat of antibioticresistant pathogens. This study aimed to develope the enhanced antibacterial activity and in-vivo efficacy of a novel truncated endolysin, CHAPSAP26-161, derived from the endolysin LysSAP26, …
Acurx presents Phase 2 results of ibezapolstat in C. difficile Infection - TipRanks.com
Acurx Pharmaceuticals announced that results from the ibezapolstat Phase 2 clinical trial in patients with C. difficile Infection, or CDI, were presented at the 17t...
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome | ACXP Stock News
Acurx Pharmaceuticals secures patent for ibezapolstat, a promising C. difficile treatment. Learn how this breakthrough could revolutionize CDI therapy, reduce recurrence, and improve gut health as Phase 3 trials approach.
Clostridium Difficile Infections Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight| Novartis AG, Astellas Pharma, Eli Lilly & Company AstraZeneca, Actelion Pharmaceuticals Ltd., Merck & Co. Inc., Baxter International Inc., Sanof
Las Vegas Nevada United States As per DelveInsight s assessment globally Clostridium Difficile Infections pipeline constitutes 20 key companies continuously working towards developing 22 Clostridium Difficile Infections treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration ...
Insoluble polysaccharides produced in plant cell cultures protect from Clostridioides difficile colitis - PubMed
Clostridioides difficile infection (CDI) poses a significant health threat due to high recurrence rates. Antimicrobial agents are commonly used to manage CDI-related diarrhoea; however, by aggravating intestinal dysbiosis, antibiotics enable C. difficile spores germination and production of toxins, …
Immuron requests pre-IND meeting for IMM-529 with FDA filing
MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new...
Exploring novel microbial metabolites and drugs for inhibiting Clostridioides difficile - PubMed
The most frequent infection associated with hospital settings is Clostridioides difficile, which can cause fatal diarrhea and severe colitis, toxic megacolon, sepsis, and leaky gut. Those who have taken antibiotics for other illnesses that affect the gut's healthy microbiota are more suscepti …
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI - PubMed
ClinicalTrials.gov identifier, NCT03183128 and NCT03183141.
Clostridium Difficile Infections Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight
Clostridium Difficile Infections companies are Vedanta Biosciences Adiso Therapeutics Finch Therapeutics Group Acurx Pharmaceuticals Mikrobiomik Healthcare Company S L Crestone MGB Biopharma Vedanta Biosciences Deinove Biovertis AG Lumen Bioscience ImmuniMed Deinove and others Las Vegas Nevada United States As per ...
Inhibition of Clostridioides difficile toxins TcdA and TcdB by the amiodarone derivative dronedarone - PubMed
The dreaded nosocomial pathogen Clostridioides difficile causes diarrhea and severe inflammation of the colon, especially after the use of certain antibiotics. The bacterium releases two deleterious toxins, TcdA and TcdB, into the gut, which are mainly responsible for the symptoms of C. difficile-as …
Fit-for-purpose heterodivalent single-domain antibody for gastrointestinal targeting of toxin B from Clostridium difficile - PubMed
Single-domain antibodies (sdAbs), such as VHHs, are increasingly being developed for gastrointestinal (GI) applications against pathogens to strengthen gut health. However, what constitutes a suitable developability profile for applying these proteins in a gastrointestinal setting remains …
The potential liver injury induced by metronidazole-provoked disturbance of gut microbiota: modulatory effect of turmeric supplementation - PubMed
It has been reported that the gut-liver axis and intestinal microbiome contribute crucially to different liver diseases. So, targeting this hepato-intestinal connection may provide a novel treatment modality for hepatic disorders such as drug-induced liver injury (DILI). The present study thought to …
Clostridium Difficile Infections Market to Expand Significantly by 2032, States DelveInsight | Rebiotix, Seres Therapeutics/ Aimmune, Summit Therapeutics, Mikrobiomik Healthcare, Acurx Pharmaceuticals
The Clostridium Difficile Infections Market Forecast report provides a thorough understanding of Clostridium Difficile Infections including historical and projected epidemiology as well as market trends in the 7MM The Clostridium Difficile Infections market is expected to surge due to the ...
Phenylthiazoles with potent & optimum selectivity toward Clostridium difficile - PubMed
Clostridium difficile (C. difficile) is one of the most threatening bacteria globally, causing high mortality and morbidity in humans and animals, and is considered a public health threat that requires urgent and aggressive action. Interruption of the human gut microbiome and the devel …
Precision antibacterials to destroy antimicrobial-resistant bacteria in oncology
Pylum Biosciences has built a technology platform to create antibacterials that target individual strains of bacteria without affecting the microbiota. Its lead preclinical programs target Clostridioides difficile for infectious disease and Fusobacterium nucleatum for colorectal cancer.